AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera

Pharmaceutical Technology | Nov 4, 2026 6:36 AM EST

AbbVie will use the Oxford site to advance treatments for immunological, neurological and oncological diseases.